Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors TM is the sole author.
Funding TM is a National Institute for Health Research (NIHR) senior investigator and also part funded by NIHR ARC North West Coast.
Disclaimer The views expressed in this article are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.
Competing interests TM has given a lecture at a meeting sponsored by Sanofi, honorarium paid to University of Liverpool.
Provenance and peer review Commissioned; internally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Antiepileptic drug treatment of rolandic epilepsy and Panayiotopoulos syndrome: clinical practice survey and clinical trial feasibility
- Weighing the risks of valproate in women who could become pregnant
- When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy
- New drugs for the treatment of epilepsy: a practical approach
- Valproate and risk of fracture in Rett syndrome
- Epilepsy and pregnancy: identifying risks
- THE BARE ESSENTIALS: Epilepsy
- Valproate and childbearing potential: new regulations
- Typical absence seizures and their treatment
- Impact of regulatory safety notices on valproate prescribing and pregnancy outcome among women of child-bearing potential in Scotland: a population-based cohort study